A Cochrane systematic review pooled 17 randomised controlled trials enrolling 4,132 men aged 50–73 to evaluate bisphosphonates, PTH/PTHrP analogues, denosumab, and romosozumab for fracture prevention — outcomes that include hip fractures, symptomatic vertebral fractures, disability, and serious adverse events. The evidence base is strikingly thin: the primary comparison (bisphosphonates vs. placebo) drew on only seven trials with 2,548 participants, and the other drug classes had far smaller pools (240–569 participants per comparison).
Osteoporosis research has been dominated by female cohorts for decades, leaving men — who account for roughly one-third of hip fractures globally and face higher post-fracture mortality than women — systematically underrepresented. This review exposes that gap sharply. With trial sizes this modest, most comparisons will be underpowered to detect meaningful differences in low-frequency events like hip fracture, and GRADE certainty ratings are likely low to very low for most outcomes. For clinicians, the practical implication is that prescribing decisions for male osteoporosis must still lean heavily on extrapolation from female trials — a scientifically uncomfortable position. Men with osteoporosis or high fracture risk (prior fracture, glucocorticoid use, hypogonadism) should discuss treatment with their physician, but they and their doctors should understand the evidence is far weaker than commonly assumed. This review is confirmatory of the evidence gap rather than paradigm-shifting; its value lies in formally quantifying what has long been suspected.